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ABSTRACT
This review details some of the advances that have been
made in the recent decade in the diagnosis, treatment
and epidemiology of pulmonary fungal infections.
These advances have occurred because of increasing
knowledge regarding the fungal genome, better under-
standing of the structures of the fungal cell wall and
cell membrane and the use of molecular epidemiologi-
cal techniques. The clinical implications of these
advances are more rapid diagnosis and more effective
and less toxic antifungal agents. For example, the diag-
nosis of invasive pulmonary aspergillosis, as well as
histoplasmosis and blastomycosis, has improved with
the use of easily performed antigen detection systems
in serum and bronchoalveolar lavage fluid. Treatment
of angioinvasive moulds has improved with the intro-
duction of the new azoles, voriconazole and posacona-
zole that have broad antifungal activity. Amphotericin
B is less frequently used, and when used is often given
as lipid formulation to decrease toxicity. The newest
agents, the echinocandins, are especially safe as they
interfere with the metabolism of the fungal cell wall, a
structure not shared with humans cells. Epidemiologi-
cal advances include the description of the emergence
of Cryptococcus gattii in North America and the
increase in pulmonary mucormycosis and pneumonia
due to Fusarium and Scedosporium species in trans-
plant recipients and patients with haematological
malignancies. The emergence of azole resistance
among Aspergillus species is especially worrisome and
is likely related to increased azole use for treatment of
patients, but also to agricultural use of azoles as fungi-
cides in certain countries.
Key words: aspergillosis, endemic mycosis, fungal
pneumonia, galactomannan test, opportunistic mycosis.
INTRODUCTION
There have been important advances in the diagnosis
and treatment of both the endemic and the opportu-
nistic mycoses, in the delineation of the epidemiology
of invasive pulmonary mould infections in immuno-
compromised patients and in the taxonomy of both
yeasts and moulds that cause pulmonary infection. In
the last decade, less well-known moulds, such as
members of the Fusarium and Scedosporium genera,
are increasingly found to cause invasive pulmonary
infection. Newly described Aspergillus species that
are pathogenic for humans are inherently more drug
resistant, and acquired resistance is increasing among
the usual species that cause human infection.
Cryptococcus gattii has emerged in North America
as a cause of pulmonary and central nervous
system (CNS) infections. Understanding of many of
these phenomena had to await the development of
molecular methods that could be applied to fungal
genomes.
Building on knowledge accrued in the last several
decades regarding the cell wall composition of
Aspergillus and the endemic fungi, Histoplasma
capsulatum and Blastomyces dermatitidis, diagnostic
tests for detecting these fungi have become a routine
part of the approach to diagnosis. Antigen detection
can be accomplished in urine, serum and body fluids,
including respiratory samples obtained by broncho-
alveolar lavage (BAL). Especially in immunocompro-
mised patients, in whom antibody responses are
notoriously poor, antigen detection has led to earlier
diagnosis and improved outcomes.
In addition to improved diagnostic techniques, the
introduction of new antifungal agents in the last
decade has occurred because of studies detailing the
synthesis of cell membranes and cell walls in yeasts
and moulds. Armed with the knowledge of the action
of fluconazole, voriconazole was synthesized specifi-
cally to allow more avid binding to the cell membrane
of moulds, allowing an increase in the antifungal
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spectrum of activity. The new generation azole agents,
voriconazole and posaconazole, have allowed safer
and more effective treatment of many fungal infec-
tions, especially treatment of invasive mould in-
fections in immunocompromised patients. Basic
knowledge of cell wall synthesis in Aspergillus and
Candida led to the development of the echinocan-
dins, which target cell wall, rather than cell mem-
brane components. By targeting a structure not
shared with mammalian cells, the echinocandins,
caspofungin, micafungin and anidulafungin are
extremely safe agents for the treatment of invasive
fungal infections.
This chapter will review new developments over the
last decade in these areas in the context of the major
fungal opportunists and endemic mycoses, and will
focus on pulmonary aspects of infections with these
fungi. The whole panoply of Aspergillus pulmonary
infections can not be addressed in this review, but





Invasive aspergillosis is by far the most common
opportunistic mould causing pulmonary infection.
There are over 900 different species of Aspergillus,
most of which do not cause human infection.1
Among the species pathogenic for humans, A. fumi-
gatus is most commonly isolated, followed by
A. flavus. There are both experimental and clinical
data suggesting that A. flavus is more virulent than
A. fumigatus, but the reasons for this have not
been elucidated.1,2 A. niger is usually a respiratory
tract commensal and rarely causes invasive infec-
tion. Two emerging species that cause invasive pul-
monary infection in highly immunosuppressed
patients are A. terreus, which is inherently amphot-
ericin B resistant, and A. ustus, which appears to be
inherently resistant to many azoles, as well as
amphotericin B.3
Aspergillus species are ubiquitous in the environ-
ment and only cause invasive disease in hosts that
have structural lung disease or defects in immune
function that allow germination of spores into
tissue-invasive hyphae.4 Risk factors for invasive pul-
monary aspergillosis include haematopoietic cell
transplant (HCT) or solid organ transplant, neutro-
penia, especially when prolonged, corticosteroids
and cytomegalovirus infection. Allogeneic HCT are
at high risk, especially if they develop chronic
graft-versus-host disease, and lung transplant recipi-
ents are at great risk because the transplanted
organ interfaces with this ubiquitous environmental
mould.1 Increasingly, reports are documenting the
emergence of invasive pulmonary aspergillosis in the
ICU setting in hosts not classically thought to be
immunosuppressed.
Brief overview of invasive
pulmonary aspergillosis
Patients usually have symptoms of fever and cough
initially; chest pain and haemoptysis follow as the
infection progresses. Other symptoms ensue if dis-
semination to skin, brain or other organs occurs. The
clinical presentation varies based on host risk factors.
For example, approximately 75% of Aspergillus infec-
tions in lung transplant recipients are limited to
the lungs, whereas disseminated infection is more
common in those who have a haematological malig-
nancy.5,6 Spread to the CNS is a dreaded complication
because of the very high mortality rate.
Radiographic techniques have improved over the
last several decades and findings highly suggestive of
invasive aspergillosis have been established in neu-
tropenic patients; these include nodules surrounded
by ground glass, the so-called ‘halo sign’, caused by
haemorrhage, and later, in the course of illness, cavi-
tation of the nodules, causing the so-called ‘air cres-
cent sign.’7 Lung transplant recipients may not have
the typical radiological findings noted for patients
who have haematological malignancy accompanied
by neutropenia. The findings are generally less spe-
cific patchy infiltrates and consolidation.8
Diagnostic considerations
The diagnosis of invasive pulmonary aspergillosis has
been a persistent challenge. Patients are often mini-
mally symptomatic early in the disease when infec-
tion might be most amenable to treatment. The
clinical presentation and radiographic findings are
not specific but are shared with other mould infec-
tions. Additionally, the microbiological diagnosis of
aspergillosis is limited by the difficulty in obtaining
appropriate biopsy material in the patient population
most at risk for invasive pulmonary disease.
There have been a number of recent developments
to aid clinicians in the diagnosis of pulmonary
aspergillosis (Table 1).9 The most important of these
has been the availability of an assay for the detection
of Aspergillus galactomannan in serum and BAL fluid.
Galactomannan is a polysaccharide cell wall compo-
nent of Aspergillus species that is released during the
growth cycle. An enzyme immunoassay (EIA) (Plate-
lia, Bio-Rad, Redmond, WA, USA) for this cell wall
component in serum has become a standard diagnos-
tic tool for invasive aspergillosis in the last decade.10,11
The results are reported as an index value, and a posi-
tive index is considered to be >0.5 in the United States.
The galactomannan assay in serum has proved most
helpful when used in the HCT population and when
serial testing is performed during the period of
highest risk for invasive aspergillosis.12 In patients
who have haematological cancers, including those
who have undergone HCT, the serum galactomannan
assay has been shown to correlate with outcome.13
However, in solid organ transplant recipients, the
serum assay has been less useful.14
The newest diagnostic tool is the detection of
Aspergillus galactomannan in BAL fluid. Not
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surprisingly, it appears to be more sensitive than the
serum assay, but the sensitivity depends upon the
population studied.15–18 The highest sensitivity (>90%)
has been reported among patients who have haema-
tological diseases;18 in solid organ transplant recipi-
ents, the sensitivity was 82%, compared with 73% for
culture and/or microscopy in one series.16 There are
an increased proportion of false positive tests when
the assay is performed on BAL fluid, most likely
reflecting colonization, especially among lung trans-
plant recipients.15 Some authors suggest that increas-
ing the index cut-off for positivity to 1.0 instead of 0.5
will improve specificity with only negligible effects on
sensitivity.17,18
The last decade also has seen a rise in studies using
real-time polymerase chain reaction (PCR) on serum,
Table 1 Methods available for the diagnosis of pulmonary fungal infections
Fungal infection Diagnostic methods Comments
Aspergillosis Culture Easily grown in lab
Histopathology Septate hyphae, but not specific for Aspergillus
CT finding of halo sign Suspect angioinvasive mould, but not specific
Galactomannan EIA in serum and BAL Has become standard test for aspergillosis in serum
and likely will become standard in BAL
RT-PCR in blood and BAL (not standardized) Likely to play an important role in future
Mucormycosis Culture Culture requires special techniques for growth
Histopathology Broad non-septate hyphae presumptive evidence
for mucormycosis
CT finding of reverse halo sign Suggestive only, not specific
RT-PCR (not standardized) Perhaps will play a larger role in future
Fusariosis Culture Easily grown in lab
Histopathology Septate hyphae resemble Aspergilllus
Characteristic skin lesions Painful lesions with hyphae seen on biopsy
PCR and in situ hybridization
(not standardized)
Both perhaps will play a larger role in future
Scedosporiosis Culture Easily grown in lab
Histopathology Septate hyphae resemble Aspergilllus
PCR and in situ hybridization
(not standardized)
Both perhaps will play a larger role in future
Cryptococcosis Culture Easily grown in lab
Histopathology Yeast forms with clear surrounding area are suggestive;
mucicarmine stain is specific
Antigen latex agglutination assay in serum,
CSF, body fluids
Highly sensitive and . . . specific; yield lower . . . yield
lower with pulmonary infection than with
disseminated and CNS infection
Blastomycosis Culture Takes 2–4 weeks to grow
Histopathology Characteristic yeast forms provide presumptive
evidence of infection
Antigen EIA in urine, serum and perhaps
body fluids
Rapid, sensitive, cross-reacts with histoplasmosis
RT-PCR (not standardized) Might play a role in future
Histoplasmosis Culture Takes 4–6 weeks to grow
Histopathology Characteristic yeast forms provide presumptive
evidence of infection
Serology Useful for acute and chronic pulmonary infection;
poor in immunocompromised host
Antigen EIA in urine, serum BAL,
other body fluids
Rapid, sensitive, cross-reacts with blastomycosis
RT-PCR (not standardized) Might play a role in future
Coccidioidomycosis Culture Easily grown; dangerous for lab; must send to reference
lab for identification for safety reasons
Histopathology Spherules large and specific; give
presumptive diagnosis
Serology Very useful for all forms of pulmonary infection
Antigen EIA in urine, serum Not clear how sensitive or specific
BAL, bronchoalveolar lavage; CNS, central nervous system; CSF, cerebrospinal fluid; CT, computed tomography;
EIA, enzyme immunoassay; RT-PCR, real-time polymerase chain reaction.
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BAL fluid and tissues as a diagnostic modality. Most
studies test for a pan-Aspergillus PCR that targets
ribosomal DNA common to all Aspergillus species;
however, primers that are used vary from laboratory
to laboratory, preventing standardization. A system-
atic review and meta-analysis noted the heterogene-
ity of results among different populations that were
studied and the lack of standardization of methods.19
Overall, the sensitivity and specificity for one positive
sample being diagnostic were 88% (75–94%) and 75%
(63–84%), respectively A recently approved commer-
cially available PCR assay for aspergillosis (MycAssay
Aspergillus, Myconostica, Manchester, UK) was found
to have sensitivity and specificity of 70% and 90%,
respectively.20 Not surprisingly, the sensitivity of PCR
is increased when BAL fluid is tested, and the speci-
ficity also appears to be high. In several recent reports,
the sensitivity and specificity for invasive aspergillosis
were 94–100% and 88–99%, respectively.21,22 Although
PCR-based tests are increasingly promising, their use
continues to be limited by lack of standardization,
and they have not yet found a place in routine clinical
practice.
Treatment options
In the last decade, the most striking change in
the treatment of invasive pulmonary aspergillosis
has been the acceptance of voriconazole as the
first-line agent for the treatment of invasive pulmo-
nary aspergillosis (Table 2).23–25 This treatment has
improved outcomes and decreased toxicity when
compared with amphotericin B therapy. Posacona-
zole also has proved effective for the treatment of
aspergillosis in a salvage trial, but has not been
studied or approved for primary therapy.26 When
amphotericin B is indicated, most physicians use a
lipid formulation to decrease the risk of nephrotoxic-
ity. The echinocandins have found a role in the treat-
ment of invasive aspergillosis, but primarily, they are
used as second-line agents when voriconazole is not
tolerated or in combination with voriconazole in an
attempt to enhance antifungal activity.24,25 Although
they are exceedingly safe agents, they are fungistatic,
and not fungicidal, against Aspergillus species and
have not been compared with amphotericin B or vori-
conazole for primary therapy of invasive aspergillosis.
An important international trial to evaluate whether
combination therapy with an echinocandin and vori-
conazole is superior to voriconazole alone for HCT
patients has been completed; hopefully, the results
will settle the long-standing debate about the efficacy
of combination antifungal therapy for aspergillosis
for the HCT population.
There have been increasing reports of azole resis-
tance in Aspergillus species. On the one hand, this is
likely related to increasing use of these agents for
both prophylaxis and treatment of fungal infections,
but on the other, there are associations with expo-
sure to azole-like compounds used in the agricultural
industry in some countries.27,28 Additionally, some
species have intrinsic resistance to various azoles.3
The primary mechanism of resistance in Aspergillus
species appears to be amino acid substitutions or
promoter alterations of the cyp51A gene, which
encodes for lanosterol 14-a-sterol demethylase, the
target enzyme of the azoles.29 Resistance to one azole
agent often confers resistance to other azoles, and
multi-azole resistance been shown to correlate with
clinical failure.30 The situation in the Netherlands is
most interesting in that azole resistance is caused
by a mutation that is unique to this outbreak and
different from those normally seen, and patients
appear to be acquiring the resistant strain from
the environment. The Netherlands is densely agri-
cultural, and azole-containing fungicides are com-
monly used, possibly increasing the development of




Mucormycosis is the term used to describe infections
caused by fungi belonging to the order Mucorales.
The term zygomycosis has fallen out of favour as
newer molecular techniques have abolished the class,
Zygomycetes. Approximately 75% of mucormycosis
cases are caused by three genera, Rhizopus, Mucor
and Rhizomucor. Mucormycosis has been increasing
in the last two decades and is now the second most
common cause of pulmonary invasive mould infec-
tions in HCT recipients.31
The organisms are ubiquitous in the environment
and, when aerosolized, may be inhaled where they
can invade into pulmonary tissues in susceptible
hosts. The Mucorales species have a particular pen-
chant to cause angioinvasion, resulting in tissue
necrosis, which likely impedes the host’s immune
response. Pulmonary mucormycosis occurs in
patients who have the most profound degree of
immune dysfunction, especially those who have a
haematological malignancy complicated by pro-
longed neutropenia and those who have received an
HCT.32 Rhino-orbital-cerebral mucormycosis also
occurs in these patients, but is more common in
patients who have poorly controlled diabetes. Other
less common predisposing factors for development of
mucormycosis include immunomodulating viral
infections, such as cytomegalovirus, trauma, iron
overload and intravenous drug use.32
The common practice of using voriconazole
for prophylaxis in markedly immunosuppressed
patients may contribute to an increased risk for
development of mucormycosis. This matter is still
controversial, but it appears that there is possibly an
association of mucormycosis with voriconazole use
in the most profoundly immunosuppressed HCT
recipients.33,34
Brief overview of pulmonary mucormycosis
Pulmonary mucormycosis causes a clinical picture
similar to that of pulmonary aspergillosis. The
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Table 2 Suggested treatment regimens for pulmonary fungal infections
Fungal infection Preferred treatment
Step-down and
second-line treatment
Aspergillosis Voriconazole, 4 mg/kg bid IV† until
stable, then step-down therapy
Step-down: voriconazole, 200 mg bid oral, until lesions
resolved
Second-line: lipid AmB, 5 mg/kg/d IV, until stable, or
posaconazole, 400 mg bid oral,‡ until lesions resolved
Mucormycosis Lipid AmB, 5 mg/kg/d IV, or higher
doses until lesions resolved
Step-down: posaconazole, 400 mg bid oral,‡ until lesions
resolved
Second-line: AmB-d, 1 mg/kg/d IV, until lesions resolved
(possible addition of echinocandin to AmB formulation)
Fusariosis Lipid AmB, 5 mg/kg/d IV, or
voriconazole, 4 mg/kg bid IV,† or
combination of lipid AmB, 5 mg/kg/d
IV, plus voriconazole, 4 mg/kg bid IV,†
until stable, then step-down therapy
Obtain susceptibilities because resistance is common
Step-down: voriconazole, 200 mg bid oral, until lesions
resolved
Second-line: posaconazole, 400 mg bid oral,‡ until lesions
resolved
Scedosporiosis Voriconazole, 4 mg/kg bid IV,† until
stable, then step-down therapy
Obtain susceptibilities because resistance is common
Step-down: voriconazole, 200 mg bid oral, until lesions
resolved
Second-line: posaconazole, 400 mg bid oral,‡ until lesions
resolved
Cryptococcosis Severe or with dissemination: lipid
AmB, 3–5 mg/kg/d IV + flucytosine,
25 mg/kg qid oral, for 2–4 weeks
Step-down: fluconazole, 400 mg qd oral, for 8–10 weeks,
then fluconazole, 200 mg for 6–12 months
Second-line: AmB-d, 0.7–1 mg/kg/d IV + flucytosine, 25 mg/kg
qid oral, for 2–4 weeks, followed by same step-down therapy
as above
(For other second-line options and differences in different
hosts, see Perfect et al.65)
Mild to moderate: fluconazole, 400 mg
qd oral, for 6–12 months
Itraconazole, 200 mg bid oral,§ or voriconazole, 200 mg bid
oral,¶ or posaconazole, 400 mg bid oral,‡ for 6–12 months
Blastomycosis Severe or immunocompromised: lipid
AmB, 3–5 mg/kg/d IV, until stable,
then step-down therapy
Add steroids for ARDS
Step-down: itraconazole, 200 mg bid oral,§ 6–12 months
Second-line: AmB-d, 0.7–1 mg/kg/d, until stable, then
itraconazole, 200 mg bid, oral,§ for 6–12 months
Mild to moderate infection:
itraconazole, 200 mg bid oral,§
for 6–12 months
Voriconazole, 200 mg bid oral,¶ or fluconazole, 800 mg qd oral,
for 6–12 months
Histoplasmosis Severe or immunocompromised: lipid
AmB, 3–5 mg/kg/d IV, until stable,
then step-down therapy
Add steroids for ARDS
Step-down: itraconazole, 200 mg bid oral,§ 6–12 months
Second-line: AmB-d, 0.7-1 mg/kg/d, IV until stable, then
itraconazole, 200 mg bid oral,§ for 6–12 months
Mild to moderate infection:
itraconazole, 200 mg bid oral,§
for 6–12 months
Voriconazole, 200 mg bid oral,¶ or fluconazole, 800 mg qd oral,
for 6–12 months
Coccidioidomycosis Severe or immunocompromised: lipid
AmB, 3–5 mg/kg/d IV, until stable,
then step-down therapy
Step-down: itraconazole, 200 mg bid oral,§ or fluconazole,
400 mg qd oral, for 12 months
Second-line: AmB-d, 0.7-1 mg/kg/d IV, until stable,
then itraconazole, 200 mg bid oral,§ or fluconazole,
400 mg qd oral, for 12 months
Mild to moderate infection:
itraconazole, 200 mg bid oral,§
or fluconazole, 400 mg qd oral,
for 6 months
Voriconazole, 200 mg bid oral,¶ or posaconazole,
400 mg bid oral,‡ for 6 months
† A loading dose of 6 mg/kg bid IV for the first day should be given.
‡ Posaconazole can also be dosed as 200 mg qid oral as long as the patient is able to comply with frequent dosing; generally,
levels are higher with more frequent dosing.
§ A loading dose of 200 mg tid oral for the first 3 days should be given.
¶ A loading dose of 400 mg bid oral for the first day should be given.
Measurement of serum concentrations of itraconazole, voriconazole and posaconazole should be performed when available to
ensure adequate absorption, look for drug interactions that might influence serum concentrations and avoid toxicity. Suggested serum
levels to aim for are: itraconazole, 1–10 mg/mL; voriconazole, 1–5.5 mg/mL; posaconazole, >1 mg/mL. There is no need to obtain serum
concentrations for fluconazole.
AmB, amphotericin B; AmB-d, amphotericin B deoxycholate; bid, two times a day; IV, intravenous; qd, every day; qid, four times a
day; tid, three times a day.
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infection tends to be rapidly progressive with promi-
nent angioinvasion. Patients complain of dyspnoea,
cough, haemoptysis and chest pain, and they usually
appear quite ill. Massive haemoptysis can occur. Less
often, and mostly in less immunocompromised
patients, the disease can be more indolent, presenting
with mass-like lesions that can cavitate. Involvement
of adjacent structures, including pleura, pericardium
and mediastinum is common.
Computed tomography (CT) scans should be
obtained at the first hint of pulmonary symptoms in
immunocompromised patients who are at risk for
mucormycosis. In patients who have haematological
malignancies, several diagnostic clues on CT scan
recently have been proposed to help differentiate
mucormycosis from infection with other angioinva-
sive moulds, especially aspergillosis. These include
the presence of multiple nodules and pleural effu-
sions and the development of a ‘reverse halo sign’ in
patients who have mucormycosis.7,35 The reverse halo
sign appears as ground-glass attenuation in the
centre of a nodule with a surrounding zone of consoli-
dation, the obverse of the typical ‘halo sign’ seen more
frequently with other moulds.7 None of these radio-
graphic findings is specific enough to make a defini-
tive diagnosis of mucormycosis, but should help in
the choice of empiric antifungal therapy until a
definitive diagnosis can be made.
Mortality rates as high as 70% have been noted in
patients who have invasive pulmonary mucormyco-
sis.32 The high mortality rates likely reflect the poor
host response, the difficulty in obtaining an early
diagnosis and the limited therapeutic arma-
mentarium. However, recent series show improved
outcomes, perhaps related to improvements in diag-
nosis, allowing earlier treatment and the use of new
antifungal agents in the last decade.36,37
Diagnostic considerations
The definitive diagnosis of mucormycosis requires
the identification of characteristic broad, non-septate
hyphae invading tissues, as well as a positive culture
yielding a member of the Mucorales order (Table 1).
However, using standard procedures for culture that
involve homogenization of tissue samples before
plating on agar, the recovery rate is only 30–50%.
When mucormycosis is a possibility, tissue obtained
by biopsy should be processed so that the fragile
hyphae are not destroyed; the sample should be very
carefully minced and placed directly on agar.38 In con-
trast, spores from these organisms are ubiquitous and
frequently contaminate culture plates in the labora-
tory. Thus, biopsy material to ascertain the presence
of hyphae in tissues is important to evaluate a culture
growing a Mucorales. Unfortunately, patients likely to
develop pulmonary mucormycosis are often thromb-
ocytopenic and can not safely undergo lung biopsy. In
an immunosuppressed patient whose CT scan shows
findings typical for an angioinvasive mould infection,
a sputum or BAL culture yielding a Mucorales is
adequate to initiate empiric treatment for pulmonary
mucormycosis.10 This is not the case in a non-
immunocompromised host, in whom a positive
culture from sputum is more likely to reflect only
contamination.
Unfortunately, there are no serological or antigen
detection assays available for mucormycosis. The
most promise has been shown with PCR assays that
can detect Mucorales to the species level in tissues.39,40
Unfortunately, none of the PCR assays have been
standardized, and only a few reference laboratories
are able to perform this procedure.
Treatment options
The treatment of mucormycosis is complex given the
reduced susceptibility of many species to currently
available antifungal agents and the extent of necrosis
that often occurs. There are no consensus guidelines
for management, but individual approaches have
been published.41 The mainstay of therapy remains
amphotericin B (Table 2). New developments in
treatment include the almost uniform use of lipid
formulations of this agent, rather than the original
deoxycholate formulation, for primary therapy and
the use of the extended spectrum azole, posaco-
nazole, for step-down therapy. Many clinicians
advocate higher doses of amphotericin B for the
treatment of mucormycosis than would be used for
other indications, and there are experimental data
that corroborate this approach.42 Others argue that
this merely enhances the toxicity without clinical
benefit. No controlled trials exist to answer this
question.
Posaconazole is currently only available as a poorly
absorbed oral suspension and thus can not be first-
line therapy for invasive mucormycosis. This agent
must be given 2–4 times daily with high fat meals or
supplements to enhance absorption.43 This is particu-
larly problematic in neutropenic patients who have
mucositis and in HCT recipients who have gas-
trointestinal graft-versus-host disease. The promise
of an intravenous formulation of posaconazole
appears to be close to reality, and this could change
the approach to therapy if initial studies show efficacy.
Voriconazole has no activity against the Mucorales.
The common use of voriconazole for empiric therapy
in immunocompromised patients who have sus-
pected invasive mould infections has the potential to
increase mortality in patients who have mucormyco-
sis because it delays the use of an effective antifungal
agent.37
There have been several adjunctive measures in the
treatment of mucormycosis brought forth in the last
decade. These include the addition of echinocandins,
the iron chelator, deferasirox and several differ-
ent immunomodulatory agents to amphotericin B
therapy.44 Echinocandins do not have activity against
the Mucorales in vitro, but there are some theoretical
reasons and experimental animal data noting that
these agents might be helpful when used in com-
bination with amphotericin B. In a small retrospec-
tive series of patients with rhino-orbital-cerebral
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mucormycosis, dual therapy with an echinocandin
and lipid amphotericin appeared to have some ben-
efit.44 This approach has not been studied in patients
with pulmonary mucormycosis and is not generally
recommended.
Some Mucorales are highly dependent on iron for
growth. Fungicidal effects against Rhizopus species
have been noted in vitro and in animal models by the
iron chelator, deferasirox. This agent has been given,
along with amphotericin B, to a few patients with gen-
erally favourable results.44 A clinical trial to study the
safety and efficacy of this treatment strategy has been
completed, but early evidence appears to show no
benefit. Immunotherapy with interferon-gamma
and/or granulocyte macrophage colony-stimulating
factor has been a promising possibility for the last





There are at least 100 Fusarium species, most of which
are plant pathogens; only a few species cause human
disease. F. solani, F. oxysporum and F. moniliforme
account for more than 90% of human infections.45
Infections in non-immunocompromised patients are
usually localized and related to direct inoculation. In
severely immunocompromised patients, pulmonary
infection is a common manifestation and occurs
either in the setting of haematogenous spread during
disseminated disease or from inhalation of conidia
into the lungs.
Scedosporium species are ubiquitous moulds that
are found in soil and water. The nomenclature has
been confusing and has been revised recently using
molecular methods. The clinically relevant species are
S. prolificans and the S. boydii (or, if in the sexual
stage, Pseudallescheria boydii) complex, which
includes S. boydii, S. aurantiacum and S. apiosper-
mum.46 S. prolificans differs from other Scedosporium
species in that it produces melanin, a common fungal
virulence factor, is able to sporulate in vivo similar
to Fusarium species and is resistant to almost all
antifungal agents.47
In the last decade, Scedosporium species have been
increasingly reported as a cause of invasive pulmo-
nary infections in solid organ transplant recipients,
HCT recipients and patients with haematological
malignancies.48,49 Pulmonary infection usually occurs
from inhalation of conidia into the alveoli but can
occur from haematogenous spread in patients with
disseminated disease.
The pathogenesis of infection with either Fusarium
species or Scedosporium species is likely similar to
that seen with aspergillosis, but infection in humans
has not been studied as intensively as aspergillosis.
Many Fusarium species produce a variety of toxins,
but it is unclear what role, if any, they play in invasive
pulmonary infection.50
Brief overview of pulmonary disease
The clinical presentation of pulmonary infection with
Fusarium and Scedosporium is similar to that noted
with Aspergillus. Patients present with fever, cough,
pleuritic chest pain and dyspnoea. CT scans usually
show nodules, often surrounded by ground-glass
opacities (halo sign) signifying angioinvasion with
resultant haemorrhage. Disseminated infection is the
rule with Fusarium infections, and non-pulmonary
manifestations can provide valuable clinical clues to
the diagnosis of this infection. Most often this is the
appearance of painful skin lesions that are manifested
as target lesions, necrotic ecthyma-like lesions, ulcer-
ations or pustules.51 Additionally, in neutropenic
patients, Fusarium species cause paronychia and
local cellulitis, which is often a harbinger of dissemi-
nated fusariosis.
Diagnostic considerations
There are currently no serological or antigen detec-
tion tests available to aid in the diagnosis of pulmo-
nary fusariosis or scedosporiosis. The definitive
diagnosis is established by growing the organism in
the laboratory (Table 1). The clinician is aided in this
endeavour by the fact that Fusarium species and
S. prolificans (but rarely organisms of the S. boydii
complex) are some of the very few moulds that are
capable of growing in blood culture bottles. As many
as 40% of patients with disseminated fusariosis have
been noted to have positive blood cultures.50 For both
genera, histopathological examination of infected
tissue demonstrates acutely branching septate
hyphae that are often undistinguishable from those of
Aspergillus species. This establishes that a patient has
disseminated infection with a septate mould, but
growth in culture is extremely important to establish
which specific organism is causing infection and
allow appropriate antifungal therapy. PCR and in situ
hybridization have been reported to be helpful in the
diagnosis of both scedosporiosis and fusariosis, but
none of these tests are standardized or approved.52,53
Treatment options
Treatment of pulmonary fusariosis remains chal-
lenging because many species are highly resistant to
antifungal agents. If culture material is available, sus-
ceptibility testing is critical for determining optimal
antifungal therapy. Several major improvements have
been seen in the last decade (Table 2). For some
patients, voriconazole and posaconazole have been
effective, both as primary treatment and as salvage
therapy when other agents have failed.54,55 Lipid for-
mulations of amphotericin B are still recommended,
and some physicians use a combination of a lipid for-
mulation of amphotericin B with voriconazole.56
There are numerous reports of clinical failure with all
of these drugs, however, and ultimately, patients who
remain neutropenic are unlikely to respond to any
antifungal agent.49
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Scedosporiosis is difficult to treat because of innate
resistance of many isolates to most antifungal agents;
importantly, this group of organisms is resistant to
amphotericin B (Table 2). S. prolificans is clearly more
resistant than organisms in the S. boydii complex.47
Voriconazole appears to be the most effective agent in
the treatment of S. apiospermum infections and has
been successful in some S. prolificans infections.57
Posaconazole also has been used in a few patients
and appeared to be effective.43 Treatment of invasive
infection with S. prolificans remains dismal.58
Cryptococcosis
Epidemiology
New developments in the epidemiology of cryptococ-
cosis in the last decade are the acceptance of C. gattii
as a separate species and the emergence of this organ-
ism in the Pacific Northwest and in scattered places
throughout the United States. C. neoformans remains
the most prevalent human pathogen in this genus
and is found worldwide in the environment. C. gattii
formerly was reported mostly from Australia and
other subtropical and tropical areas and was linked
to eucalyptus trees in these areas. The outbreak of
C. gattii in North America began on and around Van-
couver Island, British Columbia, about 12 years ago, is
not related to eucalypts and has subsequently spread
southward. Genotyping has shown that one strain
predominates in the Pacific Northwest, while other
genotypes are more common elsewhere.59
Brief overview of pulmonary cryptococcosis
Pulmonary cryptococcosis occurs in ‘normal’ hosts as
well as those who are immunocompromised. Not sur-
prisingly, the disease is generally more severe in those
who have defects in immunity and often accom-
panied by disseminated infection, including CNS
disease. In immunocompetent hosts, cryptococcosis
is more likely to be limited to the lung and occurs
more commonly in patients with chronic lung dis-
ease.60 Solid organ transplant recipients generally
develop cryptococcosis late after transplantation, and
about a third will have isolated pulmonary infection.61
The species, and perhaps even the strain, of Crypto-
coccus also has an impact on pulmonary infection; in
the recent C. gattii outbreak, pulmonary infection
was noted more frequently than previously reported
with this species.59
Immunocompetent subjects with pulmonary cryp-
tococcosis usually are asymptomatic or have mild
symptoms that include fever, malaise, cough with
sputum production and perhaps dyspnoea. Immuno-
compromised patients are much more likely to
present with fulminant infection with fever, dry cough
and dyspnoea that can progress to acute respiratory
distress syndrome (ARDS).
Imaging studies show solitary pulmonary nodules,
often pleural-based, diffuse nodules, consolidation or
diffuse bilateral infiltrates.62,63 Lymphadenopathy and
cavitation occur but are uncommon.
Diagnostic considerations
The diagnosis of pulmonary cryptococcal infection is
confirmed if the organism is grown in culture from
sputum or BAL fluid in a patient who has clinical
symptoms and radiographic findings compatible
with cryptococcosis (Table 1). In a patient who has
no radiographic findings, isolating C. neoformans
from sputum may reflect colonization. Cryptococcus
species grow readily on standard agar media and can
be easily identified by clinical laboratories. In tissues,
a clear zone, representing the capsule around the
yeast, is sometimes seen. A stain specific for Crypto-
coccus, the mucicarmine stain, should always be
performed to establish the identity of yeast-like
structures seen in tissues.
The cryptococcal antigen test is highly sensitive
and specific and is routinely used to help establish the
diagnosis of cryptococcal meningitis and dissemi-
nated cryptococcosis. However, the serum cryptococ-
cal antigen test is often negative in patients who have
isolated pulmonary infection. In fact, a positive serum
cryptococcal antigen test in a solid organ transplant
recipient who has pulmonary cryptococcosis has
been shown to reflect extrapulmonary or more severe
pulmonary disease.61
Because of the frequency of disseminated infec-
tion in immunocompromised patients, a systematic
evaluation, including cultures from blood and cere-
brospinal fluid and measurement of serum and
cerebrospinal fluid cryptococcal antigen, should
be performed in all immunosuppressed patients
who present with seemingly isolated pulmonary
cryptococcosis.64
Treatment options
Little has changed in the treatment of pulmon-
ary cryptococcosis due to either C. neoformans or
C. gattii in the last decade (Table 2).65 Therapy is
dependent upon whether the patient has isolated
pulmonary infection or has dissemination to other
organs, especially the CNS, and is also dependent on
whether the patient is immunosuppressed. In any
patient who is immunosuppressed, a lumbar punc-
ture should be performed to look for meningitis. If the
patient is immunocompetent, has minimal pulmo-
nary disease with no symptoms suggesting CNS infec-
tion and has a negative test for cryptococcal antigen
in serum, many physicians feel comfortable with not
performing a spinal tap because it is highly unlikely
that the patient has CNS involvement.63
For mild to moderate isolated pulmonary infection,
oral fluconazole for 6–12 months is recommended.65
For severe pulmonary involvement, or when con-
comitant meningitis or dissemination to other organs
is present, therapy is the same as for CNS disease:
initial treatment with amphotericin B combined with
flucytosine for 2–4 weeks, followed by consolidation
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therapy with fluconazole for an additional 8–10 weeks
and then maintenance fluconazole therapy for 6–12
months. Although amphotericin B deoxycholate is
recommended in the Infectious Diseases Society of
America (IDSA) Guidelines,65 many physicians prefer
to use a lipid formulation of amphotericin B to




B. dermatitidis, the causative agent of blastomycosis,
is a dimorphic fungus that exists as a mould in the
environment and as a yeast in tissues at 37°C. Most
cases occur in persons living in states that border the
Mississippi River basin, the Great Lakes and the St
Lawrence Seaway, and in the Canadian provinces of
Ontario and Manitoba.66 The environmental niche for
B. dermatitidis appears to be soil and decaying wood,
especially along waterways. Most cases are sporadic,
but outbreaks have been reported.
Brief overview of pulmonary blastomycosis
Infection begins with inhalation of conidia into the
alveoli, at which point the organism converts to the
yeast form. It is likely that haematogenous dissemina-
tion occurs in most patients, but clinical manifesta-
tions of this event, as well as the initial pulmonary
infection, are uncommon. Both neutrophils and cell-
mediated immunity are important in the response to
B. dermatitidis, and the histopathological picture is a
mixed pyogranulomatous process.66
Most patients with acute pulmonary infection with
B. dermatitidis remain asymptomatic or have a mild
illness with fever, dry cough, dyspnoea and mild chest
pain. A localized pulmonary infiltrate that is often
nodular is noted on chest radiograph.67 A small pro-
portion of patients with acute blastomycosis develop
overwhelming infection with ARDS.68 This is seen
most often in immunocompromised patients.
However, healthy adults, presumably who had expo-
sure to a large number of conidia, can also develop
ARDS. The mortality rate is extremely high in this
form of pulmonary blastomycosis.
Chronic forms of pulmonary blastomycosis can
present as mass-like lesions that resemble lung
cancer or as upper lobe cavitary lesions that resemble
tuberculosis or histoplasmosis. Fever, night sweats,
weight loss, fatigue, dyspnoea and cough with puru-
lent sputum and haemoptysis, are usually present for
weeks. Hilar and mediastinal lymphadenopathy are
seen less commonly than in histoplasmosis.
Cutaneous lesions are the most common manifes-
tation of disseminated extra-pulmonary blastomyco-
sis; prostate and osteoarticular involvement are less
common. The cutaneous lesions are frequently mul-
tiple, usually well circumscribed and can be verru-
cous or ulcerated. When they appear during the
course of pulmonary infection, they provide a diag-
nostic clue to the aetiology of the pneumonia;
however, often the pneumonia has cleared before the
skin lesions are manifested.
Diagnostic considerations
Growth of B. dermatitidis from a tissue biopsy or body
fluid sample sent to the laboratory remains the defi-
nitive diagnostic test for blastomycosis (Table 1). The
organism takes several weeks to grow. Once growth
occurs, identification is made quickly with a highly
specific DNA probe. However, for many patients,
the diagnosis can not be delayed for weeks and reli-
able rapid tests are essential to be able to initiate
appropriate treatment as soon as possible.
Available rapid tests include histopathological
examination of tissues, cytological examination of
body fluids, such as sputum or BAL and antigen
detection.69 The organisms are larger than most yeasts
(8–10 mm), thick-walled and have a single broad-
based bud. For an experienced pathologist, this spe-
cific morphology distinguishes B. dermatitidis from
other yeasts and is adequate to initiate therapy.
However, confirmation by growth of the organism still
should be pursued.
The newest development in the diagnosis of blas-
tomycosis is an EIA performed on urine or serum that
detects a cell wall galactomannan antigen found in
B. dermatitidis.70,71 The cell wall galactomannans for
H. capsulatum and B. dermatitidis are very similar,
and the cross-reactivity between the two assays is
close to 100%. The Blastomyces assay also cross-reacts
with antigens from Paracoccidioides brasiliensis and
Penicillium marneffei; however, these infections differ
clinically from blastomycosis and occur in different
geographic regions. Recent modifications in the
methods have improved the sensitivity of the test on
serum.
Antigen can be found in both disseminated and
pulmonary forms of blastomycosis.71,72 In one series of
27 patients who had documented blastomycosis, 21
of 26 (81%) had antigen detected in urine, and 9 of 11
(82%) had antigen detected in serum.71 The test is
probably most useful in patients who have more
severe disease with a higher burden of organisms. It is
presumed that the response to therapy can be fol-
lowed using the Blastomyces EIA, but there is minimal
experience in using this assay for follow-up testing.
A real-time PCR assay for B. dermatitidis has been
reported recently. Specificity was found to be 99% and
sensitivity 86% when compared with culture results.
Most clinical specimens were from the respiratory
tract, but specifics were not reported and the number
of patients with culture-positive blastomycosis was
only 14.73
Treatment options
All patients with symptomatic blastomycosis should
be treated with an antifungal agent. Patients who
have only a single cutaneous lesion or other focal
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manifestation should be treated for disseminated
blastomycosis. The updated IDSA guidelines for the
management of blastomycosis reflect several new
aspects of treating this disease (Table 2).74 The major
change is that treatment solely with a prolonged
course of amphotericin B deoxycholate is no longer
recommended as first-line therapy for any form of
blastomycosis. Patients who have severe infection
and those who are immunosuppressed are treated
initially with amphotericin B until stable and then
changed to an oral azole, usually within several weeks.
The guidelines suggest that either amphotericin B
deoxycholate or a lipid formulation can be used, but
in fact, most physicians now use a lipid formulation
because of the lessened toxicity of these formulations.
The second change is the increased use of azole
agents as sole therapy for mild to moderate pulmo-
nary blastomycosis. The primary agent recom-
mended is itraconazole. After the guidelines were
published, an increasing number of reports on the
use of voriconazole for blastomycosis appeared.67
This agent is considered to be second-line but has
proven effective for treating CNS infections, as well as
infection in immunosuppressed patients. Flucona-
zole is another second-line agent;74 there is little expe-
rience with posaconazole for blastomycosis.
Finally, it is important to note that some clinicians
use intravenous methylprednisolone as adjunctive
therapy to amphotericin B in patients who have ARDS
secondary to blastomycosis. Individual case reports
show success with this approach.75 This practice is
commented upon in both the IDSA and the American
Thoracic Society Guidelines, but it is not endorsed
because of insufficient evidence.25,74
Histoplasmosis
Epidemiology
The causative agent of histoplasmosis, H. capsula-
tum, is a temperature-dependent dimorphic fungus,
existing as a mould in the environment and a yeast in
tissues at 37°C.76 H. capsulatum is found primarily in
the Ohio and Mississippi River valleys and in Central
America, but other localized foci also exist in Europe,
Africa and Asia. The environmental niche for H. cap-
sulatum is soil that is enriched by the nitrogen con-
tained in bird and bat guano. Abandoned buildings
and areas under trees that serve as bird and bat roosts
and caves are especially likely to contain high concen-
trations. In the endemic areas, exposure to H. capsu-
latum is common, and most infections are sporadic.
Outbreaks have been traced back to spelunking,
demolition of buildings and activities that disrupt
contaminated soil.
Brief overview of pulmonary histoplasmosis
Infection begins when the microcondia of H. capsu-
latum are inhaled into the alveoli. Local lymphatic
spread and haematogenous dissemination occur in
most persons but are asymptomatic in most. The
major host defence against H. capsulatum is cell-
mediated immunity. The extent of disease is deter-
mined both by the number of conidia inhaled and the
immune response of the host. A small inoculum can
cause severe infection in markedly immunosup-
pressed hosts. Conversely, healthy individuals, who
most commonly have asymptomatic pulmonary
infection, can develop life-threatening pneumonia if
they inhale a large quantity of conidia.
Pulmonary infection with H. capsulatum can be
manifested as an acute self-limited pneumonia char-
acterized by fever, dry cough, mild chest discomfort
and fatigue.76,77 The chest radiograph reveals a patchy
infiltrate, and the CT scan frequently reveals small
nodules; hilar lymphadenopathy may be present and
is helpful in differentiating histoplamosis from bac-
terial pneumonias. In some patients, symptoms
are protracted, and both symptoms and radiogra-
phic findings persist for months. A small minority
of patients develops severe pneumonia that can
progress to ARDS. This is seen most often in immu-
nosuppressed patients and in those who had an over-
whelming exposure to the organism.
Chronic cavitary pulmonary histoplasmosis is a
disease of older adults who have underlying emphy-
sema. Symptoms are present for months and include
fever, fatigue, anorexia, weight loss, cough with puru-
lent sputum and haemoptysis. On chest radiographs
and CT scans, unilateral or bilateral upper lobe infil-
trates and thick-walled cavities are noted. Extensive
fibrosis and scarring are commonly seen.76
Uncommonly, patients may have persistent medi-
astinal and/or hilar lymphadenopathy following
acute pulmonary histoplasmosis. Although most
patients with this complication are asymptomatic,
the nodes can impinge on thoracic structures causing
dysphagia, chest pain, dyspnoea and cough. Medias-
tinal fibrosis is a rare complication of pulmonary his-
toplasmosis in which the host responds to infection
with excessive fibrosis that can culminate in constric-
tion of the great vessels and bronchi.77 Symptoms
include dyspnoea, cough, wheezing and haemopty-
sis. CT scan shows the extent of the fibrosis, and
angiographic studies are essential to evaluate involve-
ment of the major thoracic blood vessels.
Disseminated disease occurs in a minority of
patients with histoplasmosis; most often, this occurs
in immunosuppressed individuals. Pulmonary mani-
festations of disseminated histoplasmosis vary from
subtle diffuse nodules noted in the more chronic form
of disseminated infection to life-threatening pneu-
monia with ARDS noted in immunosuppressed
patients with acute disseminated infection.
Diagnostic considerations
Histoplasmosis is definitively diagnosed by growth of
the organism (Table 1). Sputum, BAL fluid, lung tissue
or mediastinal lymph nodes can be cultured. H. cap-
sulatum may take as long as 4–6 weeks to grow at
room temperature in the mould form. Tentative iden-
tification is made when the characteristic tuberculate
macroconidia appear, and definitive identification is
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made with the use of a commercially available highly
specific DNA probe for H. capsulatum.
Identification of the typical small (2–4 mm) oval
budding yeasts in tissue or fluid samples allows
an early diagnosis while awaiting culture results.
Methenamine silver or periodic acid Schiff stains
are needed to visualize the organisms. For patients
who have disseminated infection in addition to
pulmonary infection, bone marrow, lymph nodes,
mucous membrane lesions or skin lesions often
reveal the organisms and can obviate the need for
bronchoscopy.
Serology plays an important role in the diagnosis of
chronic cavitary pulmonary and acute pulmonary
histoplasmosis. Both complement fixation and
immunodiffusion tests should be ordered.76 For
patients with acute pneumonia, the initial studies are
often negative, but will show a fourfold rise over the
subsequent few weeks. Serology is not as useful in
immunosuppressed patients who can not mount an
antibody response.
The newest development to aid clinicians in
the diagnosis of histoplasmosis is the continuing
improvement in the sensitivity of the Histoplasma EIA
that detects a galactomannan component of the cell
wall of H. capsulatum. The original assay in urine was
shown to be positive in >90% of patients who had
AIDS and disseminated histoplasmosis, but did not
perform as well in non-AIDS patients and in those
with pulmonary infection. With modifications that
have increased the sensitivity of both the serum and
the urine assays, antigen detection now appears to be
increasingly useful for the diagnosis of disseminated
infection in non-AIDS patients and for the diagnosis
of several pulmonary syndromes.78–81 In acute pulmo-
nary histoplasmosis, a sensitivity of approximately
65% was noted for both serum and urine assays and
was more likely to be positive in those who had more
severe infection.79 Patients who have a subacute
course of pulmonary histoplasmosis are likely to have
a smaller burden of organisms and are less likely to
have a positive antigen assay.81 BAL fluid can also be
tested for Histoplasma antigen, and this test appears
to be more sensitive than cytology or culture.80 Cross-
reactivity of the Histoplasma assay is almost 100%
with the assay for B. dermatitidis because they share
similar galactomannans in their cell walls. The assay
also cross-reacts with antigens from P. brasiliensis and
P. marneffei.
A real-time PCR assay for H. capsulatum has been
reported recently. Specificity was found to be 100%
and sensitivity 73% when compared with culture
results. Most clinical specimens were from the respi-
ratory tract, but the test performed poorly with BAL
fluids for unclear reasons. The number of patients
with culture-positive histoplasmosis was only 15, so
these results must be viewed as preliminary.73
Treatment options
A major change in the last decade has been a
shift away from the use of amphotericin B deoxycho-
late towards the increasing use of azoles for many
forms of histoplasmosis (Table 2). However, ampho-
tericin B is still recommended for patients with
severe pulmonary histoplasmosis and for immu-
nosuppressed patients. The newest IDSA recom-
mendations are to use liposomal amphotericin B
preferentially over the deoxycholate formulation,
based on a controlled trial that showed the supe-
riority of this agent in AIDS patients with severe
disseminated histoplasmosis.82
Azoles are recommended as first-line treatment for
patients who have mild to moderate pulmonary his-
toplasmosis and as step-down therapy after a patient
who has severe disease has responded to initial treat-
ment with amphotericin B. Itraconazole is the drug of
choice and also is recommended for patients who
have chronic cavitary pulmonary histoplasmosis;
amphotericin B now is rarely used for this chronic
disease.
Another change is the increasing use of voricona-
zole and posaconazole for histoplasmosis. Many
times, these agents are used when a patient either can
not tolerate itraconazole or the appropriate serum
concentrations can not be achieved. There are no
controlled treatment trials, but clinical experience
has verified that these newer azoles are effective for
histoplasmosis.83 They remain second-line agents, as
does fluconazole.82
Reflecting increasing use of corticosteroids for
ARDS in the last decade, the current IDSA Guidelines
and the American Thoracic Society Guidelines more
strongly recommend the use of intravenous methyl-
prednisolone as adjunctive therapy for severe acute
pulmonary histoplasmosis.25,82 Another adjunctive,
often life-saving, measure is the increasing practice
of placing intravascular stents in order to open
major vessels impacted by mediastinal fibrosis.84 This
requires an interventionalist who is experienced in
the management of this rare disease.
Coccidioidomycosis
Epidemiology
There are now two distinct species, Coccidioides
immitis found in southern California and C. posadasii
found in other areas of the desert southwest and a few
areas in Central and South America.85 The disease
caused by these two species is indistinguishable. Coc-
cidioides species are dimorphic, existing as moulds in
the environment and as spherules in vivo. Arthro-
conidia that develop when the organism is in the
mould form are easily dispersed and inhaled into the
alveoli. In the lungs, the organism transforms into
large thick-walled spherules, which contain hundreds
of endospores. When the spherule matures, it rup-
tures and releases the endospores, which propagate
the infection.
The primary host defence against Coccidioides
species appears to be cell-mediated immunity
although neutrophils also are present in most
lesions.85 Haematogenous dissemination presumably
occurs in many patients. Dark-skinned races,
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especially African Americans, are at higher risk for




Most persons infected with Coccidioides species
have no symptoms or symptoms suggesting mild
community-acquired pneumonia.86 Fever, fatigue,
dry cough, anterior chest pain and dyspnoea are
common symptoms. Chest radiographs usually show
nodular or patchy infiltrates, and hilar lymphaden-
opathy may be present. Diffuse infiltrates with hy-
poxemia are uncommon and are usually seen in
immunosupppressed patients. Complications follow-
ing acute pneumonia occur in 5–10% of patients and
include solitary thin-walled cavities, chronic progres-
sive cavitary pneumonia and fibrosis.85 Fever, weight
loss, dyspnoea, purulent sputum and haemoptysis
are noted in patients who have chronic infection.
Disseminated infection occurs in less than 1% of
patients with symptomatic coccidioidomycosis and
may be present concomitantly with pulmonary
involvement. The sites most often involved are the
skin, subcutaneous tissues, osteoarticular structures
and meninges. Meningitis can be an isolated finding
or one component of widespread dissemination.
Diagnostic considerations
Coccidioidomycosis is definitively diagnosed when
the organism is grown in culture (Table 1). Coccidio-
ides species grow as a mould within a few days on
most standard media. It is important to warn labora-
tory personnel if coccidioidomycosis is a possibility
as the mould form is highly infectious. The large
spherules are readily identified in tissues and with the
aid of potassium hydroxide or calcofluor white, can
be identified in sputum or BAL fluid. This is extremely
helpful in establishing an early diagnosis before
culture evidence is available.
Serology is very useful in the diagnosis of coccidio-
idomycosis, especially when a reference laboratory in
the endemic area that is experienced in testing for
coccidioidomycosis performs the tests.87 An EIA is
available for screening, but the complement fixation
and immunodiffusion tests are more specific and sen-
sitive.78,87 Antibody titers are useful for both acute and
chronic pulmonary infections and for disseminated
infection. A positive antibody test for Coccidioides in
cerebrospinal fluid is diagnostic of coccidioidal men-
ingitis; many times this is the only test that is positive
in patients with isolated chronic meningitis.
In regard to new diagnostic tests, there is now a
commercially available EIA antigen detection test that
can be performed on urine or serum; experience with
this test is limited at this point. This assay was reported
to have a sensitivity of 71% in immunosuppressed
patients who had moderately severe to severe coccid-
ioidomycosis.88 Presumably further refinements will
be forthcoming to increase the sensitivity of this assay.
Treatment options
The treatment of coccidioidomycosis remains
amphotericin B in patients with severe pulmonary or
disseminated infection and oral azole therapy for
those with less severe infection (Table 2).89 Although
the IDSA Guidelines published in 2005 recommend
amphotericin B deoxycholate, most physicians now
use a lipid formulation of amphotericin B to decrease
the risk of toxicity. After a clinical response is seen,
therapy is changed to an azole. Either fluconazole or
itraconazole can be used for step-down therapy,
for mild to moderate disease and for complica-
tions of pulmonary coccidioidomycosis that require
long-term therapy. Treatment should continue for at
least 1 year, except in those patients who have mild
disease that responds promptly to therapy. Persistent
cavitary lesions that remain after adequate azole
therapy should be evaluated for possible surgical
removal.
In the last decade, there has been increasing use of
voriconazole and posaconazole for patients in whom
the first-line azole agents have failed or for patients
who have become intolerant of these agents. These
newer azole drugs probably have been used more in
coccidioidomycosis than other endemic infections
because of the inherent difficulty in obtaining a
lasting remission in this disease and the need to treat
with azoles for a prolonged period of time. In a
review of 37 patients treated with either voriconazole
or posaconazole at one centre and 33 other patients
previously reported from other medical centres, a
response rate in patients for whom either agent was
used, primarily for salvage therapy, was approxi-
mately 75% for those with pulmonary coccidioi-
domycosis.90 Both voriconazole and posaconazole
have also been used successfully for treating coccid-
ioidal meningitis, the most difficult-to-treat form of
coccidioidomycosis.
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